Tags: hepatitis C | oral Hep C drug | 3D regimen | Sapphire-I

New Hepatitis C Drug Cures 96 Percent in Trial

Monday, 18 Nov 2013 12:23 PM


AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks.
The trial is being watched closely because of the potential of the treatment, 3D regimen, to obviate the need for the injectable drug interferon, which can have debilitating side effects.
The trial, named Sapphire-I, is the first of six late-stage trials testing AbbVie's interferon-free treatment.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks. The trial is being watched closely because of the potential of the treatment, 3D regimen, to obviate...
hepatitis C,oral Hep C drug,3D regimen,Sapphire-I
74
2013-23-18
Monday, 18 Nov 2013 12:23 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved